CONCEPTION OF RISK FACTORS IN NEPHROLOGY: QUESTIONS OF PROPHYLAXIS AND TREATMENT OF CHRONIC KIDNEY DISEASE

chronic kidney disease, risk factors, prophylaxis, treatment

1. Смирнов АВ, Каюков ИГ, Есаян АМ и др. Превентивный подход в современной нефрологии. Нефрология 2004; 8(3): 7-14

2. Смирнов АВ, Есаян АМ, Каюков ИГ. Хроническая болезнь почек: на пути к единству представлений. Нефрология 2002; 6(4): 11-17

3. Есаян АМ. Тканевая ренин-ангиотензиновая система почки. Новая стратегия нефропротекции. Нефрология 2002; 6(3): 8-16

4. Каюков ИГ, Есаян АМ, Кучер АГ, Ермаков ЮА. Роль функционально-гемодинамическтх механизмов в прогрессировании хронического гломерулонефрита. Нефрология 1998; 2(1): 7-13

5. Смирнов АВ. Дислипопротеидемии и проблемы нефропротекции. Нефрология 2002; 6(2): 8-14

6. Рентц Дун Б, Андерсон Ш, Бреннер Б. Гемодинамические основы прогрессирования почечных болезней. Современная нефрология. II международный нефрологический семинар. М., 1997; 162-172

7. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006; 17(11): 2974-2984

8. Metcalfe W. How does early chronic kidney disease progress? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrol Dial Transplant 2007; 22 [Suppl 9]:ix26-30

9. Eddy AA, Neilson EG. Chronic kidney disease progression. J Am Soc Nephrol 2006; 17(11): 2964-2966

10. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005; 12(4): 353-365

11. Yu HT. Progression of chronic renal failure. Arch Intern Med 2003; 163(12): 1417-1429

12. National Kidney Foundation KD: Clinical practice guidelines for chronic Kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 2002; 39 [Suppl 1]: S1-S266

13. Мухин НА, Моисеев ВС. Пропедевтика внутренних болезней. М., 2002

14. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67(6) :2089-20100

15. Смирнов АВ, Добронравов В.А, Каюков ИГ. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9(3): 7-15

16. Meisinger C, Dцring A, Lцwel H. KORA Study Group. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J 2006; 27(10): 1245-1250

17. Vanholder R, Massy Z, Argiles A et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20(6): 1048-1056

18. Rahman M, Pressel S, Davis BR et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144(3): 172-180

19. A science advisory from the American Heart Association Kidney and Cardiovascular Disease Council. Circulation 2006; 114: 1083-1087

20. Смирнов АВ, Добронравов ВА, Каюков ИГ, Есаян АМ. Хроническая болезнь почек: дальнейшее развитие концепции и классификации. Нефрология 2007; 11(4): 7-17

21. Schmieder RE, Schrader J, Zidek W et al. Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 2007; 96(5): 247-257

22. Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension 2005; 46(1): 33-37

23. Brantsma AH, Bakker SJ, Hillege HL et al. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 2005t; 28(10): 2525-2530

24. Forman JP, Brenner BM. «Hypertension» and «microalbuminuria»: The bell tolls for thee. Kidney Int 2006; 69: 22-28

25. Hunsicker LG, Adler S, Caggiula A et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 1908–1919

26. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2–15

27. Rossing P, Hommel E, Smidt U, Parving H. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994; 37: 511–516

28. Locatelli F, Del Vecchio L, D’Amico M, Andrulli S. Is it the agent or the blood pressure level that matters for renal protection in chronic nephropathies? J Am Soc Nephrol 2002; 13[Suppl 3]: S196–S201

29. Mann JF, Gerstein HC, Yi QL et al. HOPE Investigators: Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: Results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis 2003; 42: 936–942

30. Verhave JC, Hillege HL, Burgerhof JG et al. PREVEND Study Group: The association between atherosclerotic risk factors and renal function in the general population. Kidney Int 2005; 67: 1967–1973

31. MacKinnon M, Shurraw S, Akbari A et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48(1): 8-20

32. Bakris GL, Weir MR, Secic M et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65(6): 1991-2002

33. Schaeffner ES, Kurth T, Curhan GC et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14(8): 2084-2091

34. Tonelli M, Moyй L, Sacks FM et al. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003 14(6): 1605-1613

35. Jones C, Roderick P, Harris S, Rogerson M. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant 2006; 21(8): 2133-2143